Form 4: Vericel Director Paul Wotton Reports Equity Transactions

Director Paul Wotton exercised restricted stock units and received new equity grants as part of Vericel Corporation's compensation plan.

Summary

• Director Paul Wotton exercised 3,200 Restricted Stock Units (RSUs) which vested on April 29, 2026.
• The 3,200 shares resulting from the RSU exercise were deferred into the Vericel Corporation Deferred Compensation Plan as Phantom Stock.
• The director was granted a new stock option to purchase 8,000 shares at an exercise price of $33.43.
• The director was granted an additional 3,200 RSUs scheduled to vest in 2027.
• Following these transactions, the director holds 28,802 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation and equity management.

Positives

• Director maintains a significant equity stake of 28,802 shares, aligning interests with shareholders.
• The use of deferred compensation plans indicates long-term commitment to the company's performance.

Negatives

• None identified; this is a standard compensatory filing.

Risks

• Stock options are subject to continued service requirements over a one-year vesting period.
• RSU vesting is contingent upon the date of the next Annual Meeting of Stockholders or specific anniversary dates.

Future Outlook

The director's new equity grants vest over the next year, with RSUs vesting in 2027, signaling continued board participation.

Industry Context

StockSavvy.ai notes that routine equity compensation filings for directors are standard practice in the biotechnology sector to ensure executive retention and alignment with long-term corporate governance standards.

Comparison to Industry Standards

• The equity grant structure is consistent with standard compensation packages for non-employee directors in mid-cap biotech firms.
• Deferral of vested RSUs into phantom stock is a common tax-planning and retention strategy used by corporate directors.

Stakeholder Impact

• Minimal impact on shareholders as these are standard compensatory equity grants.

Next Steps

• Vesting of 8,000 stock options in equal monthly increments over one year.
• Vesting of 3,200 RSUs on April 29, 2027, or the date of the next Annual Meeting.

Key Dates

Keywords

Vericel, VCEL, Form 4, Insider Trading, Equity Compensation, Director Compensation